Summary for Meningococcal Group B Vaccine


BreastfeedingGeriatricPediatric
  • Trade Names: Bexsero (Novartis); Trumenba (Wyeth)
  • Indications: Immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B
  • Class: Vaccine
  • Half-life: N/A
  • FDA Approval Date: 10/29/2014
  • Clinically important, potentially hazardous interactions with:
    None known

Please login to view the rest of this drug profile.

Page last updated 08/20/2025

Symbol key

Incidence - Help

<1% 1‑5% 5‑10% 10‑15% 15‑20% 20‑30% >30%

Seriousness - Help

Hospitalization possible
Life threatening
Fatal

Warnings in other populations - Help

BreastfeedingBreast feeding

GeriatricGeriatric

PediatricPediatric

Back to top